UNSPSC 51372316: Phenampromide

This classification denotes an opioid with the molecular formula C17H26N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0600L2M6EZ, chemically known as propionanilide, n-(1-methyl-2-piperidinoethyl)- but generally known as phenampromide, which bears US NIH Compound Identifier 8523. European Medicines Agency schedules Phenampromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09750MIG.

UNSPSC 51372316 Phenampromide is a Commodity code that in practice captures pharmaceutical and medical-supply procurement by state and local health agencies, though the code's nominal scope and recent solicitation activity show minimal alignment. The single recent opportunity on record—Seminole County, Florida's IFB for Naloxone and Safe Drug Deactivation Systems—involves naloxone (an opioid antagonist) and drug deactivation equipment, neither of which falls within the phenampromide product category. Phenampromide is a synthetic antimicrobial agent used primarily in industrial and agricultural applications; naloxone is an emergency-response medication with entirely different clinical and regulatory standing. State and local buyers posting under this code appear to be county health departments and similar agencies sourcing medications and medical hardware for community health programs, but the recent record does not show repeat buyers or sustained procurement volume under the code's nominal scope.

Geographic activity is limited to Florida, based on the single recent solicitation. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the response deadline was July 26, 2023 (the posting date and deadline are inconsistent in the source record). The contract offered a two-year initial term with a one-year renewal option and required E-Verify compliance, drug-free workplace certification, and standard commercial insurance. No explicit set-aside designations for disadvantaged enterprises were noted. The code shows minimal recent activity, and sourcing decisions under this code should account for the substantial mismatch between the nominal phenampromide commodity classification and the actual health-supply and pharmaceutical procurement occurring in practice.